Blood
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
Sidana S, Ahmed N, Akhtar OS, et al
This study was designed to assess the safety and effectiveness of idecabtagene vicleucel in the real world. A total of 821 patients who received idecabtagene vicleucel were evaluated from the CIBMTR registry, making this the largest real-world study of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. There was a favorable safety and efficacy profile that was consistent with published trial results, even though more than 75% of patients had significant comorbidities.
Previous Article
- • 3-Year Follow-Up From the Randomized, Phase 3 TRANSFORM Study
- • Final Results of the Phase 2 PILOT Study in Relapsed/Refractory Large B-Cell Lymphoma
- • Case Series: Lisocabtagene Maraleucel for Richter’s Transformation
- • Real-World Analysis of Lisocabtagene Maraleucel for Relapsed/Refractory Large B-cell Lymphoma
- • Implementation of a Lisocabtagene Maraleucel Outpatient Monitoring Program
- • Lisocabtagene Maraleucel Versus Second-Line Chemotherapy Regimens in the Real World
- • Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
- • Idecabtagene Vicleucel in Patients With Relapsed/Refractory Multiple Myeloma
- • Outcomes of Older Adults and Frail Patients Treated With Idecabtagene Vicleucel
- • Idecabtagene Vicleucel for Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
- • KarMMa-3 Analyses: Idecabtagene Vicleucel in Triple Class-Exposed RRMM
- • Real-World Experience: Idecabtagene Vicleucel in Older Patients With Multiple Myeloma
